Vitamin D research was once again a recurring news story this month, with more studies linking lack of vitamin D to MS.
Also widely reported was the news Novartis bought GlaxoSmithKline’s remaining rights to Ofatumumab, an investigational multiple sclerosis medicine, for up to $1 billion.
Highlight!
- Gene study finds link between multiple sclerosis and low vitamin D
- Gene study backs up link between vitamin D and multiple sclerosis risk
- Low levels of vitamin D may cause multiple sclerosis
- Vitamin D deficiency direct cause of multiple sclerosis (MS): Study
Research
- Nano Sensor Detects Multiple Sclerosis in Early Stages
- New MS Testing Model Can Predict If Disease Will Intensify in Patients
- Researchers Reveal Glucosamine As A Potential Natural Remedy For Multiple Sclerosis
- IIT-Madras team’s research to help detect multiple sclerosis
- Cortical Lesion Burden Indicative of Multiple Sclerosis Disability, Progression
- Balance Problems for Multiple Sclerosis Patients Come from T Cells
Clinical trials
- Clinical Trials Study Cannabis Chewing Gum for MS-Associated Pain and Spasticity
- AXIM Biotech Explains Cannabis Chewing Gum Clinical Trials for Pain and Spasticity Wi…
- Apitope Completes Enrollment for Phase IIa Trial for Relapsing Multiple Sclerosis
- Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification
Medical treatment news
- Access remains tricky as more patients register for cannabis oil
- Oral Disease Modifying Agents for Multiple Sclerosis Are Now More Preferred by Neurologists
- Fingolimod vs Interferon in Relapsing-Remitting Multiple Sclerosis
- Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally
Alternative/Holistic treatment news
- Mental visual imaging training improves multiple sclerosis patients’ well-being
- Neurolumen Provides Natural Alternative For Multiple Sclerosis Drugs
- Yoga: Healthy aging with an age-old practice
- Massage for multiple sclerosis
Diet
Exercise
MS Organisations
General
Business news
- Novartis Buys Rights to GSK MS Drug for $1 Billion
- Novartis (NVS) to Acquire Remaining Rights to GlaxoSmithKline’ (GSK) Ofatumumab
- Novartis acquires remaining rights to GlaxoSmithKline’s experimental drug
- “Multiple Sclerosis Market in the US 2015-2019” Published
- $54.6M Campaign Will Fund New Home for UC Neuroscience Institute
- Multiple Sclerosis Industry 2015 US Market Research Report
- Pfizer Acquires Exclusive Commercialization Rights to Generic Copaxone for Relapsing Remitting
And lastly…
___________________________________________________________________________________________________
About Willeke
Neurologically challenged by MS and personally by her will to succeed, Willeke is a disability awareness advocate seeking to improve neurological/MS services in Ireland. By highlighting difficult issues that come with such a diagnosis, she hopes her tenacity can bring some dignity to people most in need of a modern, inclusive healthcare system that looks after every aspect of life.
© Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me, 2011-2015. Unauthorized use and/or duplication of this material without express and written permission from this blog’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Willeke Van Eeckhoutte and Ireland, Multiple Sclerosis & Me with appropriate and specific direction to the original content.
It is great that research is progressing. it would be wonderful if lack of vitamin D is the link and it can be remedied!
LikeLiked by 1 person